Literature DB >> 31646663

Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita).

Hideyuki Ujiie1, Hiroaki Iwata1, Jun Yamagami2, Takekuni Nakama3, Yumi Aoyama4, Shigaku Ikeda5, Norito Ishii3, Keiji Iwatsuki6, Michiko Kurosawa7, Daisuke Sawamura8, Akiko Tanikawa2, Daisuke Tsuruta9, Wataru Nishie1, Wataru Fujimoto4, Masayuki Amagai2, Hiroshi Shimizu1.   

Abstract

The pemphigoid group is a category of autoimmune subepidermal blistering diseases in which autoantibodies deposit linearly at the epidermal basement membrane zone (BMZ). The main subtypes of pemphigoid mediated by immunoglobulin G autoantibodies are bullous pemphigoid (BP), mucous membrane pemphigoid (MMP) and epidermolysis bullosa acquisita (EBA). To establish the first guidelines approved by the Japanese Dermatological Association for the management of pemphigoid diseases, the Committee for Guidelines for the Management of Pemphigoid Diseases (Including EBA) was founded as part of the Study Group for Rare Intractable Skin Diseases under the Ministry of Health, Labor and Welfare Research Project on Overcoming Intractable Diseases. These guidelines aim to provide current information for the management of BP, MMP and EBA in Japan. Based on evidence, the guidelines summarize the clinical and immunological manifestations, pathophysiologies, diagnostic criteria, disease severity determination criteria, treatment algorithms and treatment recommendations. Because of the rarity of these diseases, there are few clinical studies with a high degree of evidence, so several parts of these guidelines were established based on the opinions of the Committee. To further optimize these guidelines, periodic revision in line with the new evidence is necessary.
© 2019 Japanese Dermatological Association.

Entities:  

Keywords:  autoimmune blistering diseases; bullous pemphigoid; epidermolysis bullosa acquisita; mucous membrane pemphigoid; treatment algorithm

Mesh:

Year:  2019        PMID: 31646663     DOI: 10.1111/1346-8138.15111

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  11 in total

1.  Epidermolysis bullosa acquisita.

Authors:  Denise Miyamoto; Juliana Olivieri Gordilho; Claudia Giuli Santi; Adriana Maria Porro
Journal:  An Bras Dermatol       Date:  2022-06-11       Impact factor: 2.113

2.  How Do Experts Treat Patients with Bullous Pemphigoid around the World? An International Survey.

Authors:  Marine Guignant; Billal Tedbirt; Dedee F Murrell; Masayuki Amagai; Valeria Aoki; Johannes Bauer; Giuseppe Ciancinni; Donna Culton; Maryam Daneshpazhooh; Dipankar De; Janet Fairley; Russell Hall; Soo-Chan Kim; Neil J Korman; Cezary Kowalewski; Daniel Mimouni; Aikaterini Patsatsi; Vivien Hebert; Marwah Adly Mohamed Saleh; Enno Schmidt; Eli Sprecher; Soner Uzun; Vanessa Venning; Victoria P Werth; Detlef Zillikens; Pascal Joly
Journal:  JID Innov       Date:  2022-04-12

3.  Methylprednisolone Plus Low-Dose Methotrexate for Bullous Pemphigoid-A Single Center Retrospective Analysis.

Authors:  Agoritsa Gravani; Georgios Gaitanis; Panagiota Spyridonos; Ioannis Alexis; Stelios Tigas; Ioannis D Bassukas
Journal:  J Clin Med       Date:  2022-06-02       Impact factor: 4.964

Review 4.  Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases.

Authors:  Hideyuki Ujiie; David Rosmarin; Michael P Schön; Sonja Ständer; Katharina Boch; Martin Metz; Marcus Maurer; Diamant Thaci; Enno Schmidt; Connor Cole; Kyle T Amber; Dario Didona; Michael Hertl; Andreas Recke; Hanna Graßhoff; Alexander Hackel; Anja Schumann; Gabriela Riemekasten; Katja Bieber; Gant Sprow; Joshua Dan; Detlef Zillikens; Tanya Sezin; Angela M Christiano; Kerstin Wolk; Robert Sabat; Khalaf Kridin; Victoria P Werth; Ralf J Ludwig
Journal:  Front Med (Lausanne)       Date:  2022-06-09

Review 5.  Current and Innovated Managements for Autoimmune Bullous Skin Disorders: An Overview.

Authors:  Kuan-Yu Chu; Hsin-Su Yu; Sebastian Yu
Journal:  J Clin Med       Date:  2022-06-19       Impact factor: 4.964

6.  A case of anti-laminin gamma-1 (p200) pemphigoid with bullous lesions on the lips, hands and feet showing antibodies to desmoglein 1.

Authors:  F Kaneko; M Ozasa; A Togashi
Journal:  Skin Health Dis       Date:  2022-02-11

7.  Drug-induced Bullous Pemphigoid and Lupus Erythematosus Occurring under Anti-TNF-α and IL-6 Therapy in a Patient with Rheumatoid Arthritis.

Authors:  Noritada Yoshikawa; Erika Matsubara; Motohisa Yamamoto; Hiroki Yamazaki; Masaaki Uehara; Masahiro Kamata; Hirotoshi Tanaka
Journal:  Intern Med       Date:  2020-07-07       Impact factor: 1.271

8.  A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder.

Authors:  Xiaoxiao Wang; Mariano Suppa; Pascal Bruderer; Nicolas Sirtaine; Sandrine Aspeslagh; Joseph Kerger
Journal:  Case Rep Oncol       Date:  2021-06-15

Review 9.  Bullous Autoimmune Dermatoses–Clinical Features, Diagnostic Evaluation, and Treatment Options.

Authors:  Nina van Beek; Detlef Zillikens; Enno Schmidt
Journal:  Dtsch Arztebl Int       Date:  2021-06-18       Impact factor: 8.251

10.  Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.

Authors:  Yihua Zhang; Qiuyun Xu; Lihong Chen; Jiawen Chen; Jing Zhang; Ying Zou; Ting Gong; Chao Ji
Journal:  Front Immunol       Date:  2021-10-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.